Therefore, agents that reduce Bcl-2, Bcl-xL and/or Mcl1 expression combined with small molecule Trk inhibitors and agents that promote mitochondrial apoptosis, would be expected to kill TrkAIII expressing tumour cells. Here, MCL1 is linked to neoplasm.